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Abstract
Objective—To document clinical and mag-
netic resonance imaging (MRI) character-
istics of a large cohort of primary and
transitional progressive multiple sclerosis
(PP and TPMS) patients over one year.
Introduction—Patients with PP or TP MS
have been shown to have low brain T2 and
T1 lesion loads and slow rates of new
lesion formation with minimal gadolin-
ium enhancement, despite their accumu-
lating disability. Serial evaluation of these
patients is needed to elucidate the patho-
logical processes responsible for disease
progression and to identify clinical and
MRI measures which can monitor these
processes in treatment trials.
Method—Patients, recruited from six Eu-
ropean centres, underwent two assess-
ments on the expanded disability status
scale (EDSS) and MRI of the brain and
spinal cord, 1 year apart.
Results—Of the 167 patients studied
(137 with PP MS and 30 with TP MS),
41 (25%; 35 PP and six TP) showed a one
step increase in the EDSS. The mean
number of new brain lesions seen was 0.88
in the PP group and 0.47 in the TP MS
group. Both groups demonstrated change
in T2 lesion load over the year (p<0.002),
with median percentage changes of 7.3%
in the PP group and 10.8% in the TP MS
group. The PP group also showed a
significant change in T1 load (p< 0.001,
median change 12.6%). The number of
new cord lesions seen was small (mean of
0.14 in the PP group and no new cord
lesions in the TP group). Both groups
demonstrated a decrease in cord cross
sectional area (p< 0.001, median changes;
PP 3.8%, TP 4.9%), but only the PP group
showed evidence of significant brain atro-
phy (p< 0.001, 0.95%).
Conclusion—Although the monitoring of
disease progression in this patient group
is diYcult, this study demonstrates
changes in both lesion load and atrophy,
which, if shown to correlate with clinical
change over a longer time will facilitate
therapeutic trial design.
(J Neurol Neurosurg Psychiatry 2000;68:713–718)
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Ten per cent of patients with multiple sclerosis
(MS) exhibit a progressive course from onset
with no history of relapse or remission; so
called primary progressive (PP) MS. Unlike
patients with relapsing-remitting (RR) or
secondary progressive (SP) MS their disability
results solely from disease progression and not
from the eVect of relapses. There is also a simi-
lar group of patients whose course is essentially
progressive with the important exception of a
single relapse or remission at any time during
disease progression or a relapse before the
onset of progression, to whom the terms tran-
sitional progressive (TP) MS has been
applied.1–3 Due to the relative rarity of both of
these clinical subtypes and their unique clinical
course, which excludes the use of relapse rate
to assess disease activity, they have largely been
excluded from therapeutic trials. Their further
evaluation could, however, teach us much
about the underlying mechanisms of disability
resulting from disease progression as distinct
from the eVect of relapses, which may in turn
facilitate appropriate trial design.
Through an EC funded initiative, MAGN-
IMS (magnetic resonance network in multiple
sclerosis), we are studying a large number of
such patients serially in a multicentre study
involving six European centres (Amsterdam,
Barcelona, Bordeaux, Lisbon, London, Milan).
Recently reported cross sectional analysis of
the baseline data4 was similar to previous stud-
ies and confirmed that patients with primary
progressive MS have a relatively older age of
onset, an equal sex ratio,5 and low mean T2
and T1 brain lesion loads.3 6 The MRI findings
in TP MS were similar to those of PP MS.1 3
The number and volume of cord lesions
diVered little between the subgroups and there
was no correlation with disability.7 8 There were
weak correlations between disability (measured
by the expanded disability status scale; EDSS)
and MRI measures of spinal cord and brain
atrophy. When this large cohort of PP and TP
MS was separated into those presenting with a
progressive spastic paraparesis compared with
any other presentation (including progressive
cerebellar, brainstem, visual, hemiplegic syn-
dromes and progressive cognitive decline), the
brain T2 and T1 lesion loads were significantly
lower in the cord onset group than the others
who demonstrated very large brain lesion
loads, approaching those of a reference SP MS
group. This showed that there is considerable
overlap in the brain and spinal cord findings
both between and within MS subtypes prevent-
ing clear cut distinction on radiological
grounds.
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The few serial studies carried out in primary
progressive MS have demonstrated a low rate
of development of new lesions9 10 and a rarity of
enhancement with gadolinium-DTPA.9
These factors, combined with the diYculties
of defining disease progression, have raised
problems in the monitoring of treatment trials
both clinically and by MRI in this patient
group.
In this study we present 1 year follow up data
of this large cohort, which provides an
opportunity to assess whether there is change
clinically or on MRI and to evaluate the
relation between them.
Methods
PATIENTS
All of the 191 patients previously studied4
throughout the six participating centres were
approached for repeat assessment 1 year later
including clinical examination and MRI. Clini-
cal measures included the Kurtzke EDSS, 10
metre timed walk, and the nine hole peg test.11
IMAGING PROTOCOL
Patients were imaged on the same scanner as
the baseline studies, which were serviced regu-
larly with no major upgrades. London and Lis-
bon scans were carried out using a Signa 1.5T
system (General Electric, Milwaukee, Wiscon-
sin, USA), the other four sites used Siemens
Magnetom 1.5T systems.
Each patient underwent T1 and T2
weighted spin echo imaging of the brain, all
sequences were acquired as contiguous, 3 mm
thick, axial slices (44 images in total). In the
spinal cord nine contiguous, 3 mm, sagittal T2
and proton density weighted slices were
obtained. A volume acquired inversion pre-
pared gradient echo acquisition of the cervical
cord (60 1 mm slices) was also performed
(Signa scanners; fast spoiled gradient echo:
FSPGR, Magnetom scanners; magnetisation
prepared rapid acquisition gradient echo:
MPRAGE) and from the data set a series of five
contiguous 3 mm axial slices (perpendicular to
the spinal cord) were reformatted using the
centre of the C2/3 disc as the caudal landmark.
The imaging parameters for each site are
detailed in the baseline data paper.4
ANALYSIS
The nine hole peg test was used as a measure of
disability by averaging the times from both
hands. When the patient was unable to perform
the task or took longer than 5 minutes to com-
plete it, the time for that hand was recorded as
300 seconds. A significant deterioration in
either the nine hole peg test or 10 metre timed
walk was defined as prolongation by 20% or
more.11
Baseline MRI analysis has been detailed
previously.4 Brain lesions on year 1 scans were
marked in a similar way with reference to the
baseline images before lesion load measure-
ment. The number of new brain lesions at year
1 was recorded by two of us (VLS and SML)
and the number and size of new spinal cord
lesions were identified by DHM.
The measures of partial brain volume and
cross sectional spinal cord area reflecting atro-
phy used in the baseline analysis were again
acquired using the methods previously
described.12 13
Measurement reproducibility was assessed
for brain lesion load, cerebral atrophy, and
cross sectional cord area by repeating measure-
ments on the baseline data set of 10 random
subjects twice, at least 1 year apart. The
coeYcient of variation (COV) was calculated
for each measure by dividing the SD by the
mean. All of the statistical analysis employed
non-parametric tests; the Mann-Whitney test
was used to look for diVerences between the
patient groups and the Wilcoxon signed ranks
test to compare the baseline and year 1 results.
Correlations were assessed using the Spear-
man’s rank correlation coeYcient. To reflect
the large number of statistical comparisons a p
value of 0.01 was considered significant and a
value between 0.01 and 0.05 a trend. No
mathematical correction of statistical signifi-
cance was carried out to avoid inflating type II
errors (the probability of accepting the null
hypothesis when the alternative is true) and
thus missing real diVerences.14
Results
Of the 191 patients originally studied 167
(87%, range within centres 83%-94%) re-
turned for repeat assessment, 137 patients with
PP disease and 30 with TP MS. The mean time
to follow up was 12.1 months (range 8-17
months). On review two patients had experi-
enced a relapse in the preceding 12 months,
one initially classified as TP became SP MS
and was excluded from the analysis, the other,
classified initially as PP, became TP MS for the
follow up analysis.
Intrarater reproducibility was assessed for
the MRI measures; the mean coeYcient of
variation (CV) for brain lesion load analysis
was 2.48% (SD 1.55), the more automated
measures of brain atrophy and cord cross
sectional area measurement produced CVs of
0.51% (SD 0.38) and 0.65% (SD 0.54)
respectively.
Forty one of the 167 patients (25%) had a
one (or more) step deterioration in the EDSS,
(an increase of 1.0 if the EDSS was<5 or an
increase of 0.5 if it was>5.0); 13 (8%) had
improved by one step. Thirty (18%) of 163
patients able to perform the nine hole peg test
had a significant deterioration, six patients
(4%) had improved. Of the 120 patients able to
walk 10 metres 36 (30%) had deteriorated and
18 patients (15% ) had improved. All three
clinical measures changed significantly in the
PP group but in the TP group only the timed
10 metre walk changed significantly (p< 0.01,
table 1).
On MRI 41.6% of the patients with PP MS
demonstrated one or more new brain lesions
and 25.5% one or more new cord lesions; when
these were combined, 43.6% of the patients
with PP had a new lesion in either brain or cord
over the 1 year study period. Within the TP
group 40.0% of patients demonstrated a new
brain lesion but no new cord lesions were seen.
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The brain MRI measure of T2 lesion load
showed an increase over 1 year in both patient
groups (PP; 7.3% median change, p<0.001,
TP; 10.8% median change, p=0.002) and the
T1 hypointensity lesion load increased signifi-
cantly in the PP group (12.6% median change,
p<0.001). There were no significant diVer-
ences between the patient groups in either
absolute change in lesion loads or in the
percentage change. In the spinal cord, lesion
load increased over the year in the PP MS
group (p=0.001) but not in the TP MS group.
The six slice measure of brain volume reflect-
ing atrophy only showed a significant change
between baseline and 1 year in the PP MS
patient group (median change 0.95%,
p<0.001). Both groups showed a significant
reduction in spinal cord area over the year, no
diVerences in the degree or rate of change were
seen between the two groups (median change
PP; 3.75%, TP; 4.91%). Seventy four per cent
of patients demonstrated a significant degree of
cord atrophy (reduction by more than twice the
COV); there was no diVerence in either clinical
or other MR measures between those with
atrophy and those without.
When the patients with PP were divided into
those who presented with a progressive cord
syndrome (112 patients) and those with any
“other presentation” (25 patients), the former
showed a significant change in EDSS from
baseline to 1 year. The number of patients with
a one step change in EDSS was not signifi-
cantly diVerent between the two groups (table
2). Both showed changes in T2 lesion load over
the year, with no diVerence in the absolute or
percentage change. However, only the cord
presentation group showed a significant change
in T1 hypointensity load (p=0.007). There was
no diVerence in the number of new brain
lesions identified. The cord presentation group
showed increased cord lesion number
(p=0.001) and volume (p=0.002) over the year
but no diVerence in absolute or percentage
change compared with the other group. Both
groups showed measurable brain and spinal
cord atrophy over the year but again no diVer-
ences in the rates of change were found.
Of the 137 patients with PP MS 16 were
receiving some kind of disease modifying treat-
ment (eight methotrexate, five azathioprine,
three cyclophosphamide) and five were partici-
Table 1 Clinical and MRI findings at baseline and year 1
Year PP (137) TP (30)
EDSS 0 Median 6.00 (2.0–8.5) 5.75 (2.5–8.5)
1 Median 6.00 (2.0–9.0)* 6.00 (2.5–8.5)
Definite deterioration 35 patients (26%) 6 patients (20%)
New brain lesions Mean 0.88 (SD 1.56) 0.47 (SD 0.63)
Median 0.00 (0–9) 0.00 (0–2)
Brain T2 load (cm3) 0 Mean 11.66 (SD 13.95) 18.16 (SD 23.13)
Median 6.65 (0–72.2)* 10.53 (0.38–102.76)*
1 Mean 13.13 (SD 15.68) 20.21 (SD 23.76)
Median 7.15 (0–74.7) 12.22 (0.39–93.35)
Change Mean 1.47 (SD 3.70) [16.0%] 2.05 (SD 4.43) [12.1%]
Median 0.33 (−6.0–20.3) [7.3%] 0.61 (−9.4–14.4) [10.8%]
Brain T1 load (cm3) 0 Mean 4.34 (SD 6.50) 6.23 (SD 11.14)
Median 1.67 (0–33.3)* 2.42 (0–54.21)
1 Mean 4.61 (SD 6.20) 6.64 (SD 9.87)
Median 2.30 (0–32.9) 3.55 (0.04–39.21)
Change Mean 0.26 (SD 2.03) [25.8%] 0.41 (SD 3.74) [23.7%]
Median 0.11 (−10.0–11.3) [12.6%] 0.24 (−15.0–10.3) [16.0%]
6 slice brain volume (cm3) 0 Mean 267.49 (SD 23.26) 265.29 (SD 21.77)
Median 269.48 (210–320)* 271.12 (205–297)
1 Mean 264.05 (SD 24.30) 264.02 (SD 21.77)
Median 265.60 (203–315) 267.59 (209–298)
Change Mean −3.44 (SD 6.85) [−1.30%] −1.28 (SD 3.37) [−0.47%]
Median −2.34 (−45.5–11.2) [−0.95%] −1.85 (−7.5–5.9) [−0.68%]
Number of cord lesions 0 Mean 2.07 (SD 2.55) 3.32 (SD 2.67)
Median 1.00 (0–12)* 2.50 (0–10)
1 Mean 2.22 (SD 2.56) 3.32 (SD 2.67)
Median 1.50 (0–12) 2.50 (0–10)
New cord lesions Mean 0.14 (SD 0.34) 0.00 (SD 0.00)
Median 0.00 (0–1) 0.00
Cord lesion load 0 Mean 2.64 (SD 3.57) 4.02 (SD 4.56)
Median 1.5 (0–18.5)* 3.0 (0–21)
1 Mean 2.81 (SD 3.60) 4.02 (SD 4.56)
Median 1.5 (0–18.5) 3.0 (0–21)
Increase in cord load Mean 0.16 (SD 0.44) 0.00 (SD 0.00)
Median 0.00 (0–2) 0.00
Cord area (mm2) 0 Mean 73.20 (SD 9.72) 72.27 (SD 9.05)
Median 73.27 (43.6–93.8)* 70.84 (55.8–86.8)*
1 Mean 70.54 (SD 10.33) 68.92 (SD 9.63)
Median 71.2 (42.9–90.0) 67.42 (52.8–83.0)
Change Mean −2.66 (SD 3.16) [−3.73%] −3.35 (SD 2.29) [−4.75%]
Median −2.85 (−13.0–4.2) [−3.75%] −3.32 (−7.1–1.4) [−4.91%]
Definite deterioration in the EDSS is defined as an increase of 1.0 if the EDSS<5 or an increase of 0.5 if >5.0.
Wilcoxon signed ranks test used to assess diVerences between baseline and year 1. Mann-Whitney test used to detect diVerences
between the patient groups in absolute and % change of MR parameters.
*p<0.01, baseline v year 1 values.
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pating in a placebo controlled trial of
interferon â-1a (treatment status unknown).15
Of the 13 patients who showed an improve-
ment in their EDSS over the year, only one of
these was in the treated group (placebo
controlled trial of interferon â-1a). If patients
on treatment were excluded from the PP MS
patient group there was no diVerence in the
absolute or percentage changes of MRI or
clinical measures between the untreated group
and the whole PP MS group, nor was there any
diVerence in the number of new brain or cord
lesions identified.
Correlations between the absolute or per-
centage change in clinical (EDSS, nine hole
peg test, and 10 metre timed walk) and MRI
measures in PP MS were poor. A one step
change in EDSS correlated with the percentage
increase in the number and volume of spinal
cord lesions (r=0.29, 0.30; p=0.019, 0.017
respectively) but not with brain lesions. None
of the baseline MR measures were predictive of
clinical change. There were, however, weak
relations between baseline clinical measures
and changes in MR measures. The baseline
EDSS correlated with the percentage change in
T2 (r=0.19, p=0.03) and T1 hypointensity
lesion loads (r=0.27, p=0.003).
Discussion
This study aims to characterise the changes in
clinical and MR parameters in both PP and TP
MS over 1 year with a view to gaining insights
into the pathological processes which result in
disease progression and disability and guiding
appropriate trial design, particularly in the
selection of outcome measures. Obviously if
large therapeutic trials are to be set up for PP
MS there must be agreement on definitions.
This study looked at two progressive groups in
detail; purely PP MS and TP MS. However,
throughout the literature there has been
disagreement on defining patients with a
history of a single relapse (before or during the
progressive phase), some groups using the term
single attack progressive MS (SAP MS)16 if the
relapse preceded progression and progressive
relapsing17 if superimposed on progression.
The recently published London Ontario
study18 included under the title of PP MS,
patients with pure PP MS and those with so
called progressive-relapsing MS; however, they
Table 2 PP MS according to presenting symptom
Year Cord presentation (112) Other (25)
EDSS 0 Median 6.00 (2.0–8.5)* 6.00 (2.0–8.5)
1 Median 6.00 (2.0–9.0) 6.00 (2.5–9.0)
Definite deterioration 31 (28%) patients 4 (16%) patients
New brain lesions Mean 0.97 (SD 1.65) 0.50 (SD 1.06)
Median 0.00 (0–9) 0.00 (0–4)
Brain T2 load (cm3) 0 Mean 9.67 (SD 10.97) 20.96 (SD 21.30)
Median 6.23 (0–62.60)* 15.43 (0.2–72.20)*
1 Mean 10.98 (SD 12.46) 23.17 (SD 23.86)
Median 6.29 (0–57.79) 15.87 (0.15–74.73)
Change Mean 1.31 (SD 3.43) [17.6%] 2.22 (SD 4.82) [8.28%]
Median 0.30 (−6.0–18.8) [7.8%] 1.09 (−3.6–20.3) [6.3%]
Brain T1 load (cm3) 0 Mean 3.67 (SD 6.10) 7.26 (SD 7.45)
Median 1.34 (0–33.30)* 5.95 (0–26.19)
1 Mean 3.90 (SD 5.91) 7.65 (SD 6.66)
Median 1.68 (0–32.9) 7.34 (0–21.87)
Change Mean 0.24 (SD 1.70) [25.7%] 0.39 (SD 3.16) [26.2%]
Median 0.09 (−5.6–11.3) [11.7%] 0.67 (−10.2–5.6) [18.4%]
6 Slice brain volume (cm3) 0 Mean 268.79 (SD 23.22) 261.77 (SD 23.09)
Median 271.40 (212.8–320.6)* 262.12 (210.3–305.8)*
1 Mean 265.43 (SD 24.51) 257.95 (SD 22.96)
Median 266.73 (203.4–315.3) 255.83 (208.2–299.5)
Change Mean −3.35 (SD 7.4) [−1.27%] −3.82 (SD 3.92) [−1.46%]
Median −2.22 (−45.6–11.2) [−0.82%] −3.14 (−10.1–3.5) [−1.19%]
Number of cord lesions 0 Mean 2.10 (SD 2.60) 2.61 (SD 2.42)
Median 1.00 (0–12)* 2.00 (0–7)
1 Mean 2.24 (SD 2.59) 2.70 (SD 2.47)
Median 2.00 (0–12) 2.00 (0–7)
New cord lesions Mean 0.14 (SD 0.35) 0.08 (SD 0.27)
Median 0.00 (0–1) 0.00 (0–1)
Cord lesion load 0 Mean 2.62 (SD 3.32) 3.30 (SD 4.31)
Median 1.50 (0–16)* 1.50 (0–18.5)
1 Mean 2.78 (SD 3.32) 3.42 (SD 4.36)
Median 1.50 (0–16) 1.50 (0–18.5)
Increase in cord load Mean 0.15 (SD 0.43) 0.11 (SD 0.39)
Median 0.00 (0–2) 0.00 (0–2)
Cord area (mm2) 0 Mean 73.03 (SD 9.89) 72.39 (SD 9.03)
Median 73.62 (43.6–93.8)* 72.00 (49.9–90.8)*
1 Mean 70.36 (SD 10.71) 69.29 (SD 9.17)
Median 71.00 (42.9–90.0) 69.96 (48.8–87.4)
Change Mean −2.68 (SD 3.22) [−3.81%] −3.10 (SD 2.73) [−4.31%]
Median −3.00 (−13.0–4.2) [−3.96%] −2.86 (−11.8–1.7) [−4.10%]
*p<0.01, baseline v year 1 values.
Definite deterioration in the EDSS is defined as an increase of 1.0 if the EDSS<5 or an increase of 0.5 if >5.0.
Wilcoxon signed ranks test used to assess diVerences between baseline and year 1. Mann-Whitney test used to detect diVerences
between the patient groups in absolute and % change of MR parameters.
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excluded patients with SAP MS (defined as a
single relapse preceding the onset of progres-
sion) reclassifying such patients as SP MS.
They also state that “a substantial minority
(28%) of the PP MS cohort had a distinct
relapse even decades after onset of progressive
deterioration”.18 Similarly in a smaller study of
both TP and PP MS by Gayou et al, 13% of PP
and 17% of TP MS were stated to have “bouts”
(relapses) during the progression phase.1 This
study, by using strict subtype definitions, hopes
to clarify whether such phenotypic subdivisions
are relevant, and by studying purely progressive
patients aims to characterise the natural history
of progressive disease distinct from any eVect
of relapses.
The limited serial studies carried out to date
have shown fewer new lesions developing over
time than patients with secondary progressive
or relapsing-remitting disease and a lower rate
of enhancement.9 10 This has raised problems
in monitoring such patients with MRI in thera-
peutic trials. Most trials rely on measures of
disease activity in the short term (new lesions,
gadolinium enhancement) and on levels of dis-
ease burden or lesion load for long term
monitoring.19 20 In PP MS it has been thought
that these measures would be unlikely to
change significantly over the usual time period
associated with clinical trials. The results of
this study suggest that this is not necessarily the
case as measurable changes in several MR
parameters have been demonstrated in this
large cohort over the relatively short period of 1
year.
Clinical change remains the primary out-
come measure in all definitive therapeutic
trials.21 To date the EDSS has been relied on
for this although it is known to have poor sen-
sitivity to change.22 Twenty five per cent of the
patients in this study showed a one step change
in EDSS over the year, this was unconfirmed
but in a cohort of purely progressive patients
this is relatively reliable. Whereas the PP
patient group showed significant change in all
three clinical measures between baseline and 1
year, change in the TP group was restricted to
the 10 metre walk although this may be a con-
sequence of the smaller sample size. The diY-
culties in measuring clinical change over short
time periods were also demonstrated in the
recently published London, Ontario natural
history cohort of PP MS23 which by their defi-
nition included patients with both pure PP MS
and the progressive-relapsing MS subgroup.17
Progression probabilities (the pobability of
progression to the next DSS level in 1 year)
were calculated for patients at each DSS level.
Even when patients were at the DSS level of 4
or 5 the progression probability was only 40%
and 33% respectively. At DSS 6 and 8 the
probabilities of progression in 1 year fell to 4%
and 2%.
In this study the rate of new lesion formation
was extremely low with less than one new brain
lesion a year in both patient groups. Despite
this there was a measurable change in the T2
lesion load in both the PP and TP patient
groups over 1 year. It is however, important to
note the disparity in the mean and median
values, indicating that the data is not normally
distributed. This is important in comparing
these data with previously published mean per-
centage change in lesion loads. Also as the pri-
mary progressive patients have considerably
smaller lesion loads, greater percentage
changes are seen with only small increases in
absolute lesion volume.24
As in previous studies of cerebral atrophy
there was a significant diVerence between
baseline and 1 year in the PP group, although
no definite change in the TP group.12 25
However, measures of spinal cord cross sec-
tional area seemed more sensitive to change
and was reduced in both groups.26
The correlations between change in the
clinical and MRI measures are poor. Change in
the EDSS correlated only with change in cord
lesion load; this is probably accounted for by
the mobility bias of the EDSS. Despite encour-
aging correlations with measures of cord
atrophy in cross sectional data, the degree of
ongoing atrophy did not correlate with changes
in any of the clinical measures. This is probably
due to the high sensitivity of the cord area
measurement, which showed significant atro-
phy in 74% of patients whereas the EDSS only
detected clinical deterioration in 25% of
patients.
When evaluating the PP patients according
to presentation only the cord onset group
showed a significant change in the EDSS
between baseline and 1 year. This may again
reflect the mobility bias of the EDSS in a
patient group where the majority have a spastic
paraparesis; alternatively the lack of change in
the other group may be a consequence of the
smaller sample size. Although the cord onset
group had considerably lower T2 and T1
hypointensity brain lesion loads, both groups
showed a definite increase in T2 lesion loads
over the year with less absolute change (but
higher percentage change) in the cord onset
group. However, only the cord group showed a
definite increase in T1 hypointensity load.
Again this may be a consequence of the diVer-
ent sample sizes, as the rate and degree of
change of T1 hypointensity lesion load were
similar in the “other presentation” group. Both
groups exhibited measurable degrees of cord
atrophy but no diVerence in the rate of change.
The results from this large cohort of patients
with PP MS suggest for the first time that there
are measurable changes in several MR param-
eters over a time period of only 1 year.
However, these changes have not been shown
to correspond with definite clinical change,
particularly with the EDSS, over 12 months in
this patient group. This may be due to the rela-
tively short study time; most clinical trials
evaluating disease progression in MS are for a
minimum time of 2 years. It is well known that
MRI changes are much more sensitive than
clinical changes.27 Comparing these data with
several recent therapeutic trials the median
percentage change in T2 lesion load (7.3% in
PP MS) is at the lower end of the range, which
is in the order of 5%-12%.21 24 27–29 The recent
European multicentre study of interferon â-1b
in SP MS reported a median increase in T2
One year follow up study of primary and transitional progressive multiple sclerosis 717
lesion load of only 1.64% in the placebo group
over the first year, this lower rate probably
reflects the larger baseline lesion loads of these
patients.30 The median absolute change in the
placebo arm of that SP MS study30 was 0.30
cm3 (median 12.6% change) at 1 year com-
pared with 0.33 cm3 in the PP patients in this
study and 0.46 cm3 in the interferon â-1a RR
MS study.24
These data show that annual lesion load
measurements could be a more useful second-
ary outcome measure than previously antici-
pated in clinical trials in PP MS. The measure-
ments of both brain and spinal cord atrophy
correlate well with the EDSS in cross sectional
studies4 12 13 31 and also demonstrate change
over 1 year.26 Longer studies are needed to
assess their clinical correlations but consider-
ing the extremely high reproducibility and level
of automation compared with the measure-
ments of brain lesion loads, they have consider-
able potential in future therapeutic trials.
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